{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T05:36:41Z","timestamp":1789969001192,"version":"4.0.1"},"reference-count":15,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"vor","delay-in-days":365,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"crossref","award":["RSG 11-186"],"award-info":[{"award-number":["RSG 11-186"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["P50CA090578"],"award-info":[{"award-number":["P50CA090578"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R01CA169259"],"award-info":[{"award-number":["R01CA169259"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"crossref","award":["R21CA17830"],"award-info":[{"award-number":["R21CA17830"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.jtho.2016.12.026","type":"journal-article","created":{"date-parts":[[2017,1,16]],"date-time":"2017-01-16T15:05:18Z","timestamp":1484579118000},"page":"878-883","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":104,"title":["Correlation between Classic Driver Oncogene Mutations in EGFR , ALK , or ROS1 and 22C3\u2013PD-L1 \u226550% Expression in Lung Adenocarcinoma"],"prefix":"10.1016","volume":"12","author":[{"given":"Deepa","family":"Rangachari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul A.","family":"VanderLaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meghan","family":"Shea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuning","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Huberman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu S.","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel B.","family":"Costa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2016.12.026_bib1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1753465815617871","article-title":"Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches","volume":"10","author":"Shea","year":"2016","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.jtho.2016.12.026_bib2","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non-small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib3","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1056\/NEJMoa1006448","article-title":"Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer","volume":"363","author":"Kwak","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib4","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive\u00a0non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib5","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.lungcan.2014.01.013","article-title":"Success and failure rates of tumor genotyping techniques in routine pathological samples with non-small-cell lung cancer","volume":"84","author":"VanderLaan","year":"2014","journal-title":"Lung Cancer"},{"key":"10.1016\/j.jtho.2016.12.026_bib6","doi-asserted-by":"crossref","first-page":"216ra177","DOI":"10.1126\/scitranslmed.3007205","article-title":"Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer","volume":"5","author":"Yasuda","year":"2013","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib7","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ctrc.2015.10.004","article-title":"Experience with targeted next generation sequencing for the care of lung cancer: insights into promises and limitations of genomic oncology in day-to-day practice","volume":"4","author":"Rangachari","year":"2015","journal-title":"Cancer Treat Commun"},{"key":"10.1016\/j.jtho.2016.12.026_bib8","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","article-title":"Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial","volume":"387","author":"Herbst","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.12.026_bib9","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.cllc.2016.05.016","article-title":"EGFR Testing in advanced non-small-cell lung cancer, a mini-review","volume":"17","author":"Sheikine","year":"2016","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.jtho.2016.12.026_bib11","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1470-2045(16)00025-5","article-title":"ALK inhibitors: plateauing systemic and intracranial activity?","volume":"17","author":"Costa","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2016.12.026_bib12","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1200\/JCO.2014.59.0539","article-title":"Clinical experience with crizotinib in patients with advanced alk-rearranged non-small-cell lung cancer and brain metastases","volume":"33","author":"Costa","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2016.12.026_bib13","first-page":"493","article-title":"Nivolumab in nonsquamous non-small-cell lung cancer","volume":"374","author":"Borghaei","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtho.2016.12.026_bib14","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1016\/S0140-6736(16)00587-0","article-title":"Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial","volume":"387","author":"Fehrenbacher","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jtho.2016.12.026_bib15","doi-asserted-by":"crossref","unstructured":"Hirsch FR, McElhinny A, Stanforth D, et\u00a0al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the \u201cBlueprint PD-L1 IHC Assay Comparison Project\u201d [e-pub ahead of print]. J Thorac Oncol. http:\/\/dx.doi.org\/10.1016\/j.jtho.2016.11.2228, accessed December 20, 2016.","DOI":"10.1016\/j.jtho.2016.11.2228"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641730014X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S155608641730014X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T22:51:49Z","timestamp":1536101509000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S155608641730014X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S155608641730014X"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2016.12.026","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3\u2013PD-L1 \u226550% Expression in Lung Adenocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2016.12.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 International Association for the Study of Lung Cancer. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}